Genetic Technologies ROE 2024

Genetic Technologies Aktienanalyse

What does Genetic Technologies do?

Genetic Technologies Ltd is an Australian biotechnology company that was founded in 1989. The company is an internationally recognized provider of genomic analysis procedures and technologies and has been operating in various business sectors since its establishment. Genetic Technologies is headquartered in Melbourne, Australia, and maintains offices in the USA, Europe, and Asia. The company's business model is based on the development and commercialization of genetic analysis systems and technologies. Genetic Technologies serves a wide range of customers, including research institutes, universities, diagnostic laboratories, biotechnology companies, and pharmaceutical companies. The company specializes in the analysis of DNA sequences and offers various genetic testing procedures to, for example, identify genetic risk factors for certain diseases or determine the ancestry of individuals. Genetic Technologies' different business sectors include clinical diagnostics, agriculture, forensic science, and scientific research. The company develops and markets various genetic testing procedures, such as the BREVAGenplus test, which aims to help women determine their risk for breast and ovarian cancer. Genetic Technologies also plays a leading role in agriculture, offering, for example, the CalfStart test, which allows breeders to determine the genetic potential of their calves. In forensic science, Genetic Technologies develops DNA tests that help solve criminal cases and identify perpetrators. Furthermore, the company also provides genetic counseling services. Another important area of Genetic Technologies is the development and commercialization of genetic analysis procedures and technologies. The company holds several patents worldwide for DNA analysis procedures, including the patented non-coding procedure, which represented a significant breakthrough in genomic research. Genetic Technologies' chairman, Dr. Mervyn Jacobson, is a recognized expert in the field of genomic research and has already authored numerous scientific publications on this topic. In addition to its various business sectors and products, Genetic Technologies has also established close relationships with other companies and institutions in the biotechnology industry. For example, the company collaborates closely with the USA-based HudsonAlpha Institute for Biotechnology to jointly develop innovative DNA technologies and procedures. Overall, Genetic Technologies has made a name for itself as a company specializing in the analysis of DNA sequences. Through its innovative products and services, the company has contributed to advancing genomic research and gaining new insights into the genetic basis of diseases and other phenomena. With its broad range of business sectors and international presence, Genetic Technologies is an important player in the biotechnology industry and is likely to further expand in the coming years. Genetic Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Genetic Technologies's Return on Equity (ROE)

Genetic Technologies's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Genetic Technologies's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Genetic Technologies's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Genetic Technologies’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Genetic Technologies stock

What is the ROE (Return on Equity) of Genetic Technologies this year?

The ROE of Genetic Technologies this year is -6.57 undefined.

How has the Return on Equity (ROE) of Genetic Technologies developed compared to the previous year?

The ROE of Genetic Technologies has increased by 1,412.76% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Genetic Technologies?

A high ROE indicates that Genetic Technologies generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Genetic Technologies?

A low ROE can indicate that Genetic Technologies is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Genetic Technologies affect the company?

A change in ROE (Return on Equity) of Genetic Technologies can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Genetic Technologies?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Genetic Technologies?

Some factors that can influence Genetic Technologies's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Genetic Technologies pay?

Over the past 12 months, Genetic Technologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genetic Technologies is expected to pay a dividend of 0 AUD.

What is the dividend yield of Genetic Technologies?

The current dividend yield of Genetic Technologies is .

When does Genetic Technologies pay dividends?

Genetic Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Genetic Technologies?

Genetic Technologies paid dividends every year for the past 0 years.

What is the dividend of Genetic Technologies?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Genetic Technologies located?

Genetic Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Genetic Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Genetic Technologies from 11/3/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.

When did Genetic Technologies pay the last dividend?

The last dividend was paid out on 11/3/2024.

What was the dividend of Genetic Technologies in the year 2023?

In the year 2023, Genetic Technologies distributed 0 AUD as dividends.

In which currency does Genetic Technologies pay out the dividend?

The dividends of Genetic Technologies are distributed in AUD.